#1 Clinical Trials Search in Europe

Mepolizumab

Mepolizumab is a monoclonal antibody medication that has been studied in clinical trials for treating several conditions characterized by high levels of eosinophils, a type of white blood cell. This article summarizes key findings from clinical trials investigating the use of mepolizumab for conditions like severe asthma, eosinophilic esophagitis, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis.

Table of Contents

What is Mepolizumab?

Mepolizumab, also known by its brand name Nucala[1], is a medication used to treat several conditions related to high levels of a type of white blood cell called eosinophils. Eosinophils are part of the body’s immune system and can cause inflammation when their levels are too high. Mepolizumab works by reducing the number of these cells in the body, which helps to decrease inflammation and alleviate symptoms in certain diseases[2].

Conditions Treated by Mepolizumab

Mepolizumab is used to treat several conditions characterized by high levels of eosinophils:

  • Severe Eosinophilic Asthma: This is a type of asthma where patients have high levels of eosinophils in their blood or lungs. Mepolizumab helps to reduce asthma attacks and improve symptoms in these patients[3].
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA): Also known as Churg-Strauss Syndrome, this is a rare blood vessel disease that causes inflammation in various organs, particularly the lungs and sinuses[4].
  • Hypereosinophilic Syndrome (HES): This is a group of rare blood disorders characterized by persistently high levels of eosinophils in the blood, which can damage various organs[5].
  • Eosinophilic Esophagitis: This is a chronic immune system disease where a type of white blood cell (eosinophil) builds up in the lining of the tube that connects your mouth to your stomach (esophagus)[6].
  • Chronic Rhinosinusitis with Nasal Polyps: This condition involves long-term swelling and irritation of the sinuses along with growths in the nose (polyps)[7].

How Mepolizumab Works

Mepolizumab is a type of medication called a monoclonal antibody. It works by targeting a specific protein in the body called interleukin-5 (IL-5). IL-5 is responsible for the production and survival of eosinophils. By blocking IL-5, mepolizumab reduces the number of eosinophils in the blood and tissues, which helps to decrease inflammation and alleviate symptoms in the conditions it treats[2][3].

How Mepolizumab is Administered

Mepolizumab is typically administered as a subcutaneous injection (an injection under the skin). The most common dose is 100 mg every 4 weeks, although the dose may vary depending on the condition being treated and the patient’s age[3][3].

The medication can be administered in different ways:

  • By a healthcare professional in a clinic
  • Self-administered by the patient or a caregiver at home using an auto-injector or a prefilled syringe

Recent studies have been conducted to evaluate the use of auto-injectors and safety syringes for self-administration of mepolizumab. These devices are designed to make it easier and safer for patients or caregivers to administer the medication at home[3][8].

Effectiveness of Mepolizumab

Clinical trials have shown that mepolizumab can be effective in treating the conditions it’s approved for:

  • Severe Eosinophilic Asthma: Mepolizumab has been shown to reduce the frequency of asthma exacerbations (sudden worsening of asthma symptoms) and improve lung function in patients with severe eosinophilic asthma[3].
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA): Studies have shown that mepolizumab can help achieve remission and reduce the need for corticosteroids in patients with EGPA[4].
  • Hypereosinophilic Syndrome (HES): Mepolizumab has been found to reduce the frequency of HES flare-ups and the need for corticosteroids in patients with this condition[5].
  • Eosinophilic Esophagitis: Research has shown that mepolizumab can reduce the number of eosinophils in the esophagus and improve symptoms in some patients with this condition[6].

Safety and Side Effects

Mepolizumab is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include[3][5]:

  • Headache
  • Injection site reactions (such as pain, redness, or swelling)
  • Back pain
  • Fatigue
  • Flu-like symptoms

Serious allergic reactions, including anaphylaxis, can occur but are rare. Patients should seek immediate medical attention if they experience signs of a severe allergic reaction such as difficulty breathing, swelling of the face or throat, or a rapid heartbeat[3].

Long-term safety studies are ongoing to further evaluate the safety profile of mepolizumab with extended use[5].

Ongoing Research

Research on mepolizumab is ongoing to further understand its effects and potential uses:

  • Studies are being conducted to evaluate the long-term safety and effectiveness of mepolizumab in various conditions[5].
  • Researchers are investigating the use of mepolizumab in other eosinophilic disorders and exploring its potential effects on epithelial cell integrity in chronic rhinosinusitis with nasal polyps[7].
  • Studies are also looking at the economic impact of mepolizumab treatment, including its effects on healthcare resource utilization and costs[9].

As research continues, our understanding of mepolizumab and its potential benefits in treating eosinophilic disorders will likely expand.

Aspect Details
Main Conditions Studied Severe eosinophilic asthma, eosinophilic esophagitis, hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis
Common Dosing 100 mg subcutaneous injection every 4 weeks
Key Outcome Measures Eosinophil counts, disease exacerbations, quality of life, lung function (in asthma), safety/tolerability
Trial Durations Typically 24-52 weeks, with some longer-term extensions
Safety Monitoring Injection site reactions, headache, back pain, allergic reactions, infections, blood cell count changes
Special Populations Some trials focus on pediatric patients or specific age groups
Administration Methods Autoinjector and safety syringe devices studied for self-administration
Economic Aspects Some trials assess changes in healthcare resource use and costs

FAQ

  • What conditions is mepolizumab being studied for in clinical trials? Mepolizumab is being studied for several conditions including severe eosinophilic asthma, eosinophilic esophagitis, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome).
  • How is mepolizumab typically administered in clinical trials? In most trials, mepolizumab is administered as a subcutaneous injection, often at a dose of 100 mg every 4 weeks. Some trials have also studied intravenous administration.
  • What are some of the main outcomes being measured in mepolizumab trials? Common outcomes include changes in eosinophil counts, frequency of disease exacerbations, quality of life measures, lung function tests in asthma trials, and safety/tolerability measures like adverse events.
  • How long do mepolizumab clinical trials typically last? The duration varies, but many trials last 24-52 weeks to assess both short-term and longer-term effects. Some have open-label extension periods lasting 1-2 years or more.
  • What are some of the potential side effects of mepolizumab being monitored? Common side effects monitored include injection site reactions, headache, and back pain. Trials also assess for less common but potentially serious effects like allergic reactions, infections, and changes in blood cell counts.

Ongoing Clinical Trials on Mepolizumab

  • Study on the Effects of Mepolizumab on Nasal Health and Immune Response in Patients with Eosinophilic Granulomatosis with Polyangiitis (eGPA)

    Recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on How Mepolizumab Affects Patients with Chronic Rhinosinusitis with Nasal Polyps

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Mepolizumab and Surgery for Patients with Chronic Rhinosinusitis with Nasal Polyps

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Extending Dosing Intervals of Mepolizumab and Dupilumab for Patients with Severe Asthma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Mepolizumab and Nasal Polypectomy for Patients with Chronic Rhinosinusitis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Stopping Mepolizumab or Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps After 12 Months Symptom-Free

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Omalizumab and Mepolizumab for Patients with Severe Allergic and Eosinophilic Asthma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

  • Access to Mepolizumab for Patients with Hypereosinophilic Syndrome

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on Mepolizumab and Drug Combination for Patients with Eosinophilic Granulomatosis with Polyangiitis

    Not recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Benralizumab and Mepolizumab for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) Receiving Standard Care

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy

Glossary

  • Eosinophil: A type of white blood cell that helps fight parasitic infections and is involved in allergic reactions and inflammation. High levels can indicate certain conditions.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body. Mepolizumab is a monoclonal antibody that targets a specific protein involved in eosinophil production.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin.
  • Exacerbation: A worsening or flare-up of a condition, such as an asthma attack.
  • Forced Expiratory Volume in 1 second (FEV1): A measure of lung function that represents the amount of air a person can forcefully exhale in one second.
  • Eosinophilic esophagitis: A chronic immune condition where eosinophils build up in the esophagus, causing inflammation and difficulty swallowing.
  • Hypereosinophilic syndrome: A group of rare blood disorders characterized by persistently high levels of eosinophils in the blood and tissues.
  • Eosinophilic granulomatosis with polyangiitis: A rare autoimmune condition characterized by inflammation of blood vessels, asthma, and high levels of eosinophils.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.

References

  1. https://clinicaltrials.gov/study/NCT04578171
  2. https://clinicaltrials.gov/study/NCT01691859
  3. https://clinicaltrials.gov/study/NCT03099096
  4. https://clinicaltrials.gov/study/NCT03557060
  5. https://clinicaltrials.gov/study/NCT03306043
  6. https://clinicaltrials.gov/study/NCT00358449
  7. https://clinicaltrials.gov/study/NCT05895929
  8. https://clinicaltrials.gov/study/NCT03021304
  9. https://clinicaltrials.gov/study/NCT04550780